| Brussels,
June 5, 2003 - Janssen Pharmaceutica
is performing in line with expectations.
In 2002 the company achieved a sales
volume of 1,674 million euros
and a net profit of 282 million euros.
In Belgium the workforce rose by 280
persons, making a total of 4,234 employees.
The investments are particularly striking,
188 million euros having been
put into buildings, equipment and
new technology and 805 million euros
into research & development. Furthermore,
the company is working on a number
of very promising new products, which
is certain to generate growth in the
future.
Strong financial
results
Janssen Pharmaceutica realizes
most of its sales volume within the
Johnson & Johnson group of companies.
The volume rose by 6.8% to 1,674 million
euros. At 282 million euros, net profit
was as projected, i.e. at around the
same level as in the previous year.
|
|
|
In 2002 the company embarked on an ambitious investment
program in both R&D and production. R&D
expenditure rose by 30 million euros to 805 million
euros, and the outlay for salaries increased by
35 million euros to 337 million euros. Cash flow
was 945 million euros. The cash flow course over
recent years shows that the financial base of the
company is fundamentally sound. High
points of 2002
2002 was for Janssen Pharmaceutica a year of
record investment in buildings and equipment.
The first stone was laid for the new buildings
of the Discovery Research (67 million euros) and
Drug Safety & Evaluation (44 million
euros) departments, and the Clinical Supply Unit
was renovated and expanded (16 million euros).
In addition, the Pharmaceutical Development building,
which represents a total investment of 50 million
euros, was officially opened. Finally, in a collaborative
arrangement with the Jan Palfijn hospital in Merksem,
further investment was made in a new center for
clinical research.
A total of 32 million euros was invested in new
technology, including an impressive IT project
that will streamline existing logistics processes
in pharmaceutical production.
As for production, Janssen is
actively involved in the worldwide production
of CYPHER™, the stent from its affiliate
Cordis.
Investing in research
Investments in R&D reached a record level
of 805 million euros. In 2002, 9 new substances
were submitted for registration, 13 were approved
and 10 drugs were launched on the market.
At the moment there are 38 new substances in the
initial evaluation phase. Research focuses on
gastrointestinal diseases, diseases of the central
nervous system, metabolic disorders, oncology
and infectious diseases.
The results of Johnson & Johnson
In 2002 Johnson & Johnson realized a sales
volume of 36.3 billion dollars, 12.3% up over
the previous year. With a turnover of 17.2 billion
dollars the pharmaceutical franchise accounted
for 47% of this amount. The net profit of the
franchise was 6.6 billion dollars.
Within the Johnson & Johnson group, Janssen
Pharmaceutica is a worldwide Center of
Excellence of integrated R&D, production and
general services. In Belgium the company
has sites in Beerse, Geel and Olen and these employ
of a total of 4,234 staff. In addition, more than
250 persons work at Janssen-Cilag in Berchem,
which is responsible for the Belgian and Luxembourg
markets. With more than 80 drugs to its name,
the company is one of the most innovative in the
world and its products are used worldwide in human
and veterinary medicine and material protection.
The company is active in a wide variety of areas,
such as gastroenterology, central nervous system
disorders, oncology, pain control and infectious
diseases.
|
